phrykt

Agios Pharmaceuticals, Inc. (AGIO): who owns it and who trades it

As of Nov 16, 2026, AGIO insiders reported 29 open-market sales worth $4.3M and no purchases in the last 12 months, with 96% of the sale value made under pre-set 10b5-1 plans. The largest seller was Brian Goff (CEO), with $1.7M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Agios Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors and Congress mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AGIO

237 funds and institutions reported AGIO shares worth $2.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 10.9%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.10.9%
Farallon Capital Management, L.l.c.9.9%
State Street Corp5.9%
Lynx1 Capital Management LP5.7%
D. E. Shaw & Co., Inc.5.2%
Vanguard Portfolio Management LLC4.9%
Vanguard Capital Management LLC4.5%
California State Teachers Retirement System4.2%
Armistice Capital, LLC4.0%
Erste Asset Management GmbH3.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.6.46M10.86%$240M+12%
Farallon Capital Management, L.l.c.5.92M9.95%$220M+4%
State Street Corp3.53M5.94%$131M+5%
Lynx1 Capital Management LP3.41M5.73%$127M+31%
D. E. Shaw & Co., Inc.3.11M5.22%$115M+16%
Vanguard Portfolio Management LLC2.90M4.87%$108M+11%
Vanguard Capital Management LLC2.68M4.51%$99.5M+2%
California State Teachers Retirement System2.48M4.17%$66.8M+3515%
Armistice Capital, LLC2.40M4.04%$89.1M-12%
Erste Asset Management GmbH2.15M3.62%$82M-20%
Nomura Asset Management International Inc.2.11M3.55%$78.3M+41%
Geode Capital Management, LLC1.57M2.65%$58.4M+7%
Susquehanna International Group, LLP1.38M2.31%$51M+2%
ADAR1 Capital Management, LLC1.29M2.17%$47.8M+816%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.1.28M2.15%$47.5M-19%
Dimensional Fund Advisors LP1.25M2.10%$46.3M+8%
GW&K Investment Management, LLC1.21M2.03%$44.8M-1%
Goldman Sachs Group Inc1.15M1.94%$42.7M+43%
UBS Group AG985,8311.66%$36.6M+644%
Morgan Stanley963,2561.62%$35.7M-0%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AGIO insiders reported $0 of open-market purchases and $4.3M of sales. 96% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$4.3M
29 trades, 7 people
Sales under a 10b5-1 plan
96%
Share of sale value
Latest trade
Oct 26, 2026
Filed Oct 28, 2026

Purchases and sales by month

$1.2M$1.2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 26, 2026Sarah GheuensChief Medical OfficerSale plan7,866$37.69$296KForm 4
Oct 22, 2026Sarah GheuensChief Medical OfficerSale plan500$37.52$18.8KForm 4
Oct 21, 2026Sarah GheuensChief Medical OfficerSale plan1,489$37.53$55.9KForm 4
Aug 4, 2026Sarah GheuensChief Medical OfficerSale plan30,000$30.48$914KForm 4
Jul 1, 2026Sarah GheuensChief Medical OfficerSale plan4,007$37.56$151KForm 4
Apr 2, 2026James William BurnsChief Legal OfficerSale plan3,280$34.71$114KForm 4
Apr 2, 2026Sarah GheuensChief Medical OfficerSale plan2,940$34.71$102KForm 4
Apr 2, 2026Cecilia JonesCFOSale plan3,141$34.71$109KForm 4
Apr 2, 2026Tsveta MilanovaChief Commercial OfficerSale plan3,262$34.71$113KForm 4
Apr 2, 2026Krishnan ViswanadhanChief Corp Dev & StrategSale plan2,959$34.71$103KForm 4
Apr 2, 2026Brian GoffCEOSale plan12,472$34.71$433KForm 4
Apr 2, 2026Brian GoffCEOSale plan6,596$34.71$229KForm 4
Mar 5, 2026Krishnan ViswanadhanChief Corp Dev & StrategSale plan2,959$27.80$82.3KForm 4
Mar 3, 2026Theodore James Washburn Jr.Principal Accounting OffSale5,272$28.88$152KForm 4
Mar 2, 2026Brian GoffCEOSale plan5,918$28.96$171KForm 4
Mar 2, 2026Brian GoffCEOSale plan3,870$28.96$112KForm 4
Mar 2, 2026Brian GoffCEOSale plan8,267$28.96$239KForm 4
Mar 2, 2026James William BurnsChief Legal OfficerSale plan1,187$28.96$34.4KForm 4
Mar 2, 2026James William BurnsChief Legal OfficerSale plan1,681$28.96$48.7KForm 4
Mar 2, 2026James William BurnsChief Legal OfficerSale plan1,163$28.96$33.7KForm 4
Mar 2, 2026Cecilia JonesCFOSale plan594$28.96$17.2KForm 4
Mar 2, 2026Cecilia JonesCFOSale plan1,573$28.96$45.6KForm 4
Mar 2, 2026Theodore James Washburn Jr.Principal Accounting OffSale plan698$28.96$20.2KForm 4
Mar 2, 2026Theodore James Washburn Jr.Principal Accounting OffSale plan727$28.96$21.1KForm 4
Mar 2, 2026Theodore James Washburn Jr.Principal Accounting OffSale plan798$28.96$23.1KForm 4
Jan 5, 2026Tsveta MilanovaChief Commercial OfficerSale plan2,872$27.02$77.6KForm 4
Dec 30, 2025James William BurnsChief Legal OfficerSale plan2,932$27.09$79.4KForm 4
Dec 30, 2025Brian GoffCEOSale plan12,473$27.09$338KForm 4
Dec 30, 2025Brian GoffCEOSale plan6,230$27.09$169KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Brian GoffChief Executive Officer, Director–$1.7MApr 2, 2026
Sarah GheuensChief Medical Officer–$1.5MOct 26, 2026
James William BurnsChief Legal Officer–$310KApr 2, 2026
Theodore James Washburn Jr.Principal Accounting Officer–$217KMar 3, 2026
Tsveta MilanovaChief Commercial Officer–$191KApr 2, 2026
Krishnan ViswanadhanChief Corp Dev & Strategy–$185KApr 2, 2026
Cecilia JonesChief Financial Officer–$172KApr 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AGIO short interest

High short interest. 10.9% of AGIO shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went down 12%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.52M AGIO shares were sold short, 10.9% of the shares outstanding, down 5.4% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 5.2 trading days (days to cover).

Shares short, % of all shares

10.9%May 15Oct 3013.1%

Days to cover

5.2May 15Oct 3010.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.52M10.91%-5%1.26M5.2
Oct 15, 20266.89M11.55%-2%1.23M5.6
Sep 30, 20267.02M11.75%-7%1.09M6.4
Sep 15, 20267.56M12.66%+0%798,8619.5
Aug 31, 20267.54M12.62%-1%893,0378.4
Aug 14, 20267.63M12.78%+12%1.09M7.0
Jul 31, 20266.84M11.46%+3%1.33M5.1
Jul 15, 20266.63M11.15%-2%1.03M6.4
Jun 30, 20266.76M11.36%-2%1.33M5.1
Jun 15, 20266.90M11.60%-0%1.04M6.6
May 29, 20266.93M11.65%-7%848,5658.2
May 15, 20267.45M12.53%+7%859,1038.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded AGIO

Since Nov 17, 2024, 1 member of Congress reported 5 purchases and 0 sales of AGIO. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Aug 20, 2026, reported Sep 10, 2026.

Purchases 5Sales 0

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Aug 20, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfSep 10, 2026Report
Mar 3, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfApr 7, 2026Report
Dec 11, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfJan 12, 2026Report
Apr 17, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfMay 6, 2025Report
Jan 29, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfFeb 11, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Agios Pharmaceuticals company events

Agios Pharmaceuticals filed 6 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Jul 30, 2026ResultsReleased financial results. Filing
  3. Jun 18, 2026LeadershipAt the 2026 Annual Meeting of Stockholders of Agios Pharmaceuticals, Inc. held on June 18, 2026, the Company’s stockholders approved an amendment to the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan. Filing
  4. Apr 29, 2026ResultsReleased financial results. Filing
  5. Feb 12, 2026ResultsReleased financial results. Filing
  6. Jan 12, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Agios Pharmaceuticals financials

Famous investors that hold AGIO

5 of the 50 well-known investors we track reported holding AGIO in their latest 13F filing. The largest position is Ken Griffin's, worth $25.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026778,581$25.9M0.0%+6%
Jim Simons · Renaissance TechnologiesQ3 2026505,600$16.8M0.0%New
Larry Robbins · Glenview Capital ManagementQ3 2026459,792$15.3M0.3%New
Israel Englander · Millennium ManagementQ3 2026274,439$9.1M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202652,832$1.8M0.0%-20%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named AGIO in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Lynx1 Capital Management LP13G/A0.8%
Nov 16, 2026D. E. Shaw & Co., L.P.13G/A6.5%
Nov 16, 2026D. E. Shaw & Co., L.P.13G/A6.5%
Nov 16, 2026Lynx1 Capital Management LP13G/A0.8%
Nov 13, 2026Morgan Stanley13G5.7%
Nov 13, 2026Morgan Stanley13G5.7%

Questions about Agios Pharmaceuticals, Inc. (AGIO) stock

Who owns the most AGIO stock?

The largest reported owner of Agios Pharmaceuticals, Inc. (AGIO) is BlackRock, Inc., with 10.9% of the company. In total, 237 funds and institutions reported holding AGIO at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are AGIO insiders buying or selling?

In the last 12 months, AGIO insiders reported no open-market purchases and 29 sales worth $4.3M. The latest trade was on Oct 26, 2026. See every trade.

What is the short interest in AGIO?

As of Oct 30, 2026, 6.52M AGIO shares were sold short, 10.9% of the shares outstanding, down 5.4% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 5.2 trading days (days to cover). See the history.

Have members of Congress traded AGIO?

Yes. 1 member of Congress reported 5 purchases and 0 sales of AGIO since Nov 17, 2024. The latest was reported on Sep 10, 2026. See the trades.

Which famous investors hold AGIO?

5 of the 50 well-known investors we track reported AGIO in their latest 13F filing, including Ken Griffin, Jim Simons, Larry Robbins. The largest position is worth $25.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.